Biogen Inc. (NASDAQ:BIIB) Shares Bought by Sentry Investment Management LLC
Sentry Investment Management LLC increased its stake in Biogen Inc. (NASDAQ:BIIB) by 1.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,037 shares of the biotechnology company’s stock after buying an additional 377 shares during the period. Sentry Investment Management LLC’s holdings in Biogen were worth $7,392,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in BIIB. Capital Guardian Trust Co. increased its stake in shares of Biogen by 130.1% in the fourth quarter. Capital Guardian Trust Co. now owns 359 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 203 shares during the last quarter. Crestwood Advisors Group LLC acquired a new stake in Biogen during the first quarter worth $106,000. Winfield Associates Inc. increased its stake in Biogen by 16.8% in the first quarter. Winfield Associates Inc. now owns 467 shares of the biotechnology company’s stock worth $128,000 after buying an additional 67 shares in the last quarter. Focused Wealth Management Inc increased its stake in Biogen by 18.8% in the fourth quarter. Focused Wealth Management Inc now owns 475 shares of the biotechnology company’s stock worth $135,000 after buying an additional 75 shares in the last quarter. Finally, Rational Advisors LLC increased its stake in Biogen by 14.3% in the first quarter. Rational Advisors LLC now owns 593 shares of the biotechnology company’s stock worth $162,000 after buying an additional 74 shares in the last quarter. Institutional investors and hedge funds own 87.36% of the company’s stock.
Shares of Biogen Inc. (NASDAQ BIIB) opened at 280.81 on Friday. The company has a 50-day moving average price of $259.24 and a 200-day moving average price of $274.78. The firm has a market capitalization of $59.56 billion, a price-to-earnings ratio of 17.59 and a beta of 0.78. Biogen Inc. has a 12 month low of $240.07 and a 12 month high of $333.65.
Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, April 25th. The biotechnology company reported $5.20 EPS for the quarter, beating the consensus estimate of $4.97 by $0.23. The firm had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.73 billion. Biogen had a return on equity of 38.17% and a net margin of 30.17%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the company earned $4.79 earnings per share. Equities analysts forecast that Biogen Inc. will post $20.47 EPS for the current fiscal year.
A number of equities research analysts have weighed in on the stock. UBS AG upgraded shares of Biogen from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $262.00 to $270.00 in a research note on Monday, June 19th. Jefferies Group LLC reiterated a “hold” rating and set a $310.00 price target on shares of Biogen in a research note on Tuesday, July 11th. Vetr upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $306.48 price target on the stock in a research note on Wednesday. William Blair reiterated an “outperform” rating on shares of Biogen in a research note on Monday, June 26th. Finally, Morgan Stanley reiterated an “equal weight” rating on shares of Biogen in a research note on Monday, July 10th. Thirteen investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $325.48.
In other Biogen news, Director Brian S. Posner sold 1,084 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $256.31, for a total value of $277,840.04. Following the completion of the transaction, the director now directly owns 6,330 shares in the company, valued at $1,622,442.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Paul J. Clancy sold 9,892 shares of the stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $290.00, for a total value of $2,868,680.00. Following the completion of the transaction, the vice president now owns 10,813 shares of the company’s stock, valued at $3,135,770. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by company insiders.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.